Cargando…

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Manabu, Ohta, Tsuyoshi, Sugiyama, Akiko, Sakaki, Hirotsugu, Sudo, Takeshi, Tsutsumi, Seiji, Shigeta, Shogo, Tokunaga, Hideki, Toyoshima, Masafumi, Yaegashi, Nobuo, Nagase, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112827/
https://www.ncbi.nlm.nih.gov/pubmed/30174791
http://dx.doi.org/10.18632/oncotarget.25868
_version_ 1783350911124373504
author Seino, Manabu
Ohta, Tsuyoshi
Sugiyama, Akiko
Sakaki, Hirotsugu
Sudo, Takeshi
Tsutsumi, Seiji
Shigeta, Shogo
Tokunaga, Hideki
Toyoshima, Masafumi
Yaegashi, Nobuo
Nagase, Satoru
author_facet Seino, Manabu
Ohta, Tsuyoshi
Sugiyama, Akiko
Sakaki, Hirotsugu
Sudo, Takeshi
Tsutsumi, Seiji
Shigeta, Shogo
Tokunaga, Hideki
Toyoshima, Masafumi
Yaegashi, Nobuo
Nagase, Satoru
author_sort Seino, Manabu
collection PubMed
description INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. CONCLUSION: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. MATERIALS AND METHODS: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.
format Online
Article
Text
id pubmed-6112827
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61128272018-08-31 Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel Seino, Manabu Ohta, Tsuyoshi Sugiyama, Akiko Sakaki, Hirotsugu Sudo, Takeshi Tsutsumi, Seiji Shigeta, Shogo Tokunaga, Hideki Toyoshima, Masafumi Yaegashi, Nobuo Nagase, Satoru Oncotarget Research Paper INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. CONCLUSION: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. MATERIALS AND METHODS: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system. Impact Journals LLC 2018-08-10 /pmc/articles/PMC6112827/ /pubmed/30174791 http://dx.doi.org/10.18632/oncotarget.25868 Text en Copyright: © 2018 Seino et al. https://creativecommons.org/licenses/by/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Seino, Manabu
Ohta, Tsuyoshi
Sugiyama, Akiko
Sakaki, Hirotsugu
Sudo, Takeshi
Tsutsumi, Seiji
Shigeta, Shogo
Tokunaga, Hideki
Toyoshima, Masafumi
Yaegashi, Nobuo
Nagase, Satoru
Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title_full Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title_fullStr Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title_full_unstemmed Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title_short Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
title_sort metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112827/
https://www.ncbi.nlm.nih.gov/pubmed/30174791
http://dx.doi.org/10.18632/oncotarget.25868
work_keys_str_mv AT seinomanabu metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT ohtatsuyoshi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT sugiyamaakiko metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT sakakihirotsugu metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT sudotakeshi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT tsutsumiseiji metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT shigetashogo metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT tokunagahideki metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT toyoshimamasafumi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT yaegashinobuo metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel
AT nagasesatoru metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel